TC Medical(SH:600763) Sou Hu Cai Jing·2025-12-09 12:27Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Tongce Medical (600763) as of December 9, 2025, with a closing price of 41.5 yuan, reflecting a decrease of 0.57% [1] - The company reported a main revenue of 2.29 billion yuan for the first three quarters of 2025, showing a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [2] - In the third quarter of 2025, the company achieved a single-quarter main revenue of 842 million yuan, which is a 2.34% increase year-on-year, and a net profit of 192 million yuan, reflecting a 2.31% year-on-year growth [2] Group 2 - The company's debt ratio stands at 25.1%, with investment income reported at 41.22 million yuan and financial expenses at 31.93 million yuan, resulting in a gross profit margin of 41.69% [2] - Over the past 90 days, seven institutions have provided ratings for the stock, with four giving a buy rating and three an increase rating, while the average target price set by institutions is 5.288 billion yuan [2] - On December 9, 2025, the net inflow of main funds was 5.03 million yuan, accounting for 4.05% of the total transaction amount, while retail investors experienced a net outflow of 7.47 million yuan, representing 6.01% of the total transaction amount [1]